Bio/Pharma News

AstraZeneca Sells Antibiotics Business to Pfizer

August 24, 2016

The portfolio in this agreement include approved antibiotics Merrem, Zinforo, and Zavicefta, as well as candidates in clinical development, ATM-AVI and CXL.

Pfizer to Acquire Medivation

August 22, 2016

Pfizer will acquire Medivation for approximately $14 billion.

Casebia Therapeutics Begins Operations

August 19, 2016

The joint venture, created through a collaboration with Bayer and CRISPR Therapeutics, will be based in Cambridge, MA.

Janssen Secures Breakthrough Therapy Designation for Depression Drug

August 16, 2016

The company received breakthrough therapy designation for esketamine, a treatment for major depressive disorder with imminent risk for suicide.

Mallinckrodt to Merge with Stratatech Corporation

August 15, 2016

Mallinckrodt announced a planned merger agreement with Stratatech Corporation, a regenerative medicine company.

Novartis Expands Biologics Production in France

August 15, 2016

Jacobs Engineering will provide engineering and construction services to expand the Novartis site in Huningue, France.

Allergan Plans to Expand in New Jersey

August 15, 2016

The EDA offered Allergan tax credits in order to encourage the company to remain in the state.

Pfizer to Lay Off 151 in Pearl River Vaccines Phase-Out

August 12, 2016

Pearl River had set the scene for vaccine breakthroughs, cGMP challenges, and ambitious Lean and operational excellence programs

Biogen Announces Name of Hemophilia Spin-Off Business

August 11, 2016

The company announced that Bioverativ will be the name of its new hemophilia spin-off business, which is expected to launch in early 2017.

Bristol-Myers Squibb Reacquires Rights to ASLAN002

August 10, 2016

BMS will reacquire the rights to ASLAN002 (BMS777607) from ASLAN Pharmaceuticals in China, Australia, Korea, Taiwan, and other Asian territories.